Xaira Therapeutics

Founded in 2024 and based in the San Francisco Bay Area, Xaira Therapeutics is a new but prominent biotechnology company that integrates artificial intelligence (AI) into drug development. The company was co-founded by Marc Tessier-Lavigne, known for his scientific and academic expertise, and David Baker, who is noted for his innovations at the University of Washington’s Institute of Protein Design. Xaira Therapeutics aims to advance the way drugs are developed by solving complex biological challenges through AI, enhancing how medicines are discovered and improving patient care.

NewsHeat chart

  • Week
  • Month
  • Year
  • Media news
  • Corp news
Click to unlock the chart

The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice

Company Valuation

  • Valuation
  • Share Price
  • Cumulative Funding

The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.

Funding Round
Funding Amount
Post-Money Valuation
Share Price
Venture24 Apr, 2024

*** - To view the data, please log into your account or create a new one.

News related to Xaira Therapeutics1

Filter by
Sort by
Xaira Therapeutics
Apr 25, 2024 Show on chart

Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs

The advances in foundational models come from the University of Washington’s Institute of Protein Design ...



Lux CapitalLux Capital
SV AngelSV Angel
Lightspeed Venture PartnersLightspeed Venture Partners
New Enterprise AssociatesNew Enterprise Associates
Sequoia CapitalSequoia Capital
Menlo VenturesMenlo Ventures